BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis

Cell, Journal Year: 2018, Volume and Issue: 172(1-2), P. 176 - 190.e19

Published: Jan. 1, 2018

Language: Английский

---

Tuberculosis

The Lancet, Journal Year: 2019, Volume and Issue: 393(10181), P. 1642 - 1656

Published: March 20, 2019

Language: Английский

---

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

New England Journal of Medicine, Journal Year: 2018, Volume and Issue: 379(2), P. 138 - 149

Published: July 11, 2018

Recent Mycobacterium tuberculosis infection confers a predisposition to the development of disease, leading killer among global infectious diseases. H4:IC31, candidate subunit vaccine, has shown protection against disease in preclinical models, and observational studies have indicated that primary bacille Calmette-Guérin (BCG) vaccination may offer partial infection.In this phase 2 trial, we randomly assigned 990 adolescents high-risk setting who had undergone neonatal BCG receive H4:IC31 revaccination, or placebo. All participants negative results on testing for M. QuantiFERON-TB Gold In-tube assay (QFT) human immunodeficiency virus. The outcomes were safety acquisition infection, as defined by initial conversion QFT was performed every 6 months during 2-year period. Secondary immunogenicity sustained positive test without reversion status at 3 after conversion. Estimates vaccine efficacy are based hazard ratios from Cox regression models compare each with placebo.Both vaccines immunogenic. occurred 44 308 (14.3%) group 41 312 (13.1%) group, compared 49 310 (15.8%) placebo group; rate 8.1% 6.7% 11.6% group. Neither nor prevented conversion, point estimates 9.4% (P=0.63) 20.1% (P=0.29), respectively. However, reduced an 45.4% (P=0.03); 30.5% (P=0.16). There no clinically significant between-group differences rates serious adverse events, although mild-to-moderate injection-site reactions more common revaccination.In which reflect high-transmission setting. This finding inform clinical new candidates. (Funded Aeras others; C-040-404 ClinicalTrials.gov number, NCT02075203 .).

Language: Английский

---

Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection

Clinical Microbiology Reviews, Journal Year: 2018, Volume and Issue: 31(4)

Published: July 17, 2018

SUMMARY Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a limited understanding its clinical pathogenic spectrum infection and disease. Historically, scientific research, diagnostic testing, drug treatment have focused on addressing one two disease states: latent TB or active Recent research has clearly demonstrated that human infection, from disease, exists within continuous metabolic bacterial activity antagonistic immunological responses. This revised leads us propose additional incipient subclinical TB. The recognition TB, which helps divide along spectrum, provides opportunities for development therapeutic interventions prevent progression transmission bacilli. In this report, we review current pathogenesis, immunology, epidemiology, diagnosis, treatment, prevention both emerging states an ancient bacterium.

Language: Английский

---

Alveolar Macrophages Provide an Early Mycobacterium tuberculosis Niche and Initiate Dissemination

Cell Host & Microbe, Journal Year: 2018, Volume and Issue: 24(3), P. 439 - 446.e4

Published: Aug. 23, 2018

Language: Английский

---

Nanotechnology approaches for global infectious diseases

Nature Nanotechnology, Journal Year: 2021, Volume and Issue: 16(4), P. 369 - 384

Published: March 22, 2021

Language: Английский

---

Far-UVC light: A new tool to control the spread of airborne-mediated microbial diseases

Scientific Reports, Journal Year: 2018, Volume and Issue: 8(1)

Published: Feb. 5, 2018

Airborne-mediated microbial diseases such as influenza and tuberculosis represent major public health challenges. A direct approach to prevent airborne transmission is inactivation of pathogens, the antimicrobial potential UVC ultraviolet light has long been established; however, its widespread use in settings limited because conventional sources are both carcinogenic cataractogenic. By contrast, we have previously shown that far-UVC (207-222 nm) efficiently inactivates bacteria without harm exposed mammalian skin. This because, due strong absorbance biological materials, cannot penetrate even outer (non living) layers human skin or eye; viruses micrometer smaller dimensions, can inactivate them. We show for first time aerosolized viruses, with a very low dose 2 mJ/cm2 222-nm inactivating >95% H1N1 virus. Continuous dose-rate indoor locations promising, safe inexpensive tool reduce spread airborne-mediated diseases.

Language: Английский

---

Anti-tuberculosis treatment strategies and drug development: challenges and priorities

Nature Reviews Microbiology, Journal Year: 2022, Volume and Issue: 20(11), P. 685 - 701

Published: April 27, 2022

Despite two decades of intensified research to understand and cure tuberculosis disease, biological uncertainties remain hamper progress. However, owing collaborative initiatives including academia, the pharmaceutical industry non-for-profit organizations, drug candidate pipeline is promising. This exceptional success comes with inherent challenge prioritizing multidrug regimens for clinical trials revamping trial designs accelerate regimen development capitalize on discovery breakthroughs. Most wanted are markers progression from latent infection active pulmonary response predictors relapse, in vitro tools uncover synergies that translate clinically animal models reliably assess treatment shortening potential new regimens. In this Review, we highlight benefits challenges 'one-size-fits-all' duration versus individualized therapy based disease severity host pathogen characteristics, considering scientific operational perspectives.

Language: Английский

---

Immune evasion and provocation by Mycobacterium tuberculosis

Nature Reviews Microbiology, Journal Year: 2022, Volume and Issue: 20(12), P. 750 - 766

Published: July 25, 2022

Language: Английский

---

Building a tuberculosis-free world: The Lancet Commission on tuberculosis

The Lancet, Journal Year: 2019, Volume and Issue: 393(10178), P. 1331 - 1384

Published: March 1, 2019

Language: Английский

---